Residual solvents in peptide raw materials: read the test basis

A residual-solvent report for a peptide raw material should name the solvents assessed, the analytical procedure, the result units and the material basis. A general statement that a sample was “solvent tested” leaves the scope of the result unclear.

Build the solvent list from the supply history

Ask which solvents may remain from the actual manufacturing and purification route. A standard screening panel can be useful, but its list needs to cover the material under review. When the route changes, repeat that discussion even if the catalogue name and appearance stay the same.

The enquiry should identify whether the sample is an isolated powder, a formulated lyophilised presentation or another preparation. This affects how a result relates to the mass received. Keep any carrier or other component visible in the material description. Procurement cannot reconstruct the denominator from a chromatogram alone.

Distinguish a solvent result from a counter-ion statement

Commercial documents sometimes combine several different questions under a general impurity heading. Ask the laboratory to state whether it measured named volatile solvents, a counter-ion or another residual component. A report for one of those purposes should not be treated as a complete answer to the others.

Read ICH Q3C values within their pharmaceutical scope

ICH Q3C(R9), dated 24 January 2024, addresses residual solvents in pharmaceuticals. For acetonitrile, it lists a permitted daily exposure of 4.1 mg/day and an Option 1 concentration of 410 ppm. Option 1 uses an assumed product mass of 10 g/day. The Class 3 discussion relates 5000 ppm, or 0.5%, to that same exposure context. These figures explain the guideline; they are not universal research-peptide release limits or instructions for administering a material. [1]

A quotation that says “Q3C compliant” still needs to identify the solvent list, agreed specification and applicable basis. For a research enquiry, put the intended laboratory application and required evidence in the order. Any regulated product project needs its own responsible quality and regulatory assessment.

Check units before comparing reports

For a mass-fraction result, 1 ppm is equivalent to 1 microgram per gram. Consider a hypothetical result of 200 ppm in an as-received sample weighing 0.50 g:

200 micrograms/g × 0.50 g = 100 micrograms of the named solvent

This is a unit-conversion example, not a supplied-lot result or an acceptance recommendation. The calculation works only if the laboratory’s ppm value is a mass fraction on the stated basis. A concentration reported in the prepared analytical solution needs the appropriate preparation calculation before it can describe the original material.

Ask what “not detected” means

A report should connect that phrase to a named analyte, a method and a stated detection or reporting limit. A numerical value below a laboratory’s quantitation limit has a different status from a reliable quantified result. Keep those statuses separate when entering values into a supplier-comparison sheet.

For example, two hypothetical suppliers could report “not detected” and “below the quantitation limit” for the same solvent. Those statements cannot be ranked until the limits and reporting conventions are known. A more detailed report can look less reassuring while actually providing more useful information.

Define what the analytical procedure covers

Q3C(R9) discusses chromatographic procedures, including gas chromatography, and explicitly includes solvent volatility as a method-validation consideration. Naming headspace GC therefore describes an approach, not proof that every relevant solvent is covered. [1] ICH Q2(R2) provides the broader framework for matching the measurement range and selectivity to the analytical purpose. [2]

Resolve the purchasing decision before approving the report

• Confirm the actual material form and offered lot.
• Agree which residual components require separate results.
• Check that the analytical scope covers the named solvents.
• Record result units, basis and reporting limits.
• Assign ownership for interpreting any result outside the agreed specification.

Keep the residual-solvent review with the broader batch COA review. For additional testing, send the analyte list to analytical services. A lyophilised powder development brief should also state whether the requested presentation changes the material basis used in the report.